Clinical trial
A multicentre double blind placebo controlled clinical trial to assess efficacy and safety of Alvalin� (cathine hydrochloride) vs. placebo in 265 obese patients/group with a body mass index (BMI) between 30 and 45 kg/m2
Primary endpoint is the weight reduction of at least 10% overall in the treatment group with at least 5% greater weight reduction than in the placebo group) after 52 weeks of treatment.
| Category | Value |
|---|---|
| Study start date | 2012-10-15 |